Clinical Trial Detail

NCT ID NCT03287817
Title CD19/22 CAR T Cells (AUTO3) for the Treatment of Diffuse Large B Cell Lymphoma (ALEXANDER)
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Autolus Limited
Indications

primary mediastinal B-cell lymphoma

B-cell lymphoma

diffuse large B-cell lymphoma

Therapies

Pembrolizumab

Cyclophosphamide + Fludarabine

CD19/CD22 CAR T cells

Age Groups: adult senior

No variant requirements are available.